AWAKN-P001 Is a N-methyl-D-aspartate Receptor-Modulating Drug Used in Combination with Psycho-Social Support for The Treatment of Severe Alcohol Use Disorder...
Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety Psychedelics biotech Cybin (NYSE: CYBN) and UK-based Small...
Functional mushroom company Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) following the company’s release of its unaudited financials for the quarter...
The brain health brand took in its first institutional capital with plans to go into over 1,800 retail stores in the next year.
Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed. The post News...
On Monday, Cybin released the financial results for its first quarter, ending June 30, 2023. As of June 30, 2023, the company had $9.4 million (Canadian...
If all warrants are exercised, an additional $160 million comes into play. The post Compass Pathways Lands $125M Investment appeared first on Green Market...
COMPASS Pathways has announced a capital raise of up to $285 million, the largest cash injection the industry has seen in quite some time. The post COMPASS...
COMPASS Pathways has been making waves since its inception, and this year is no exception. The company released its second-quarter financial report and...
Cybin reports first quarter financial results and business highlights, including updates on key trials. The post Cybin Reports Q1 Financial Results and...